CALIDI BIOTHERAPEUTICS (CLDI) reported an 8-K filing on October 27, 2025, confirming the divestiture of its majority-owned subsidiary, Nova Cell, Inc.
CLDI entered agreements to sell 100% of Nova Cell for total consideration valued at \(6.0 million plus ongoing royalties. The \)6.0 million closing payment is structured primarily through the cancellation of approximately \(1.215 million in existing indebtedness (Promissory Note) and \)4.785 million in Deferred Consideration.
Payment and Royalty Structure: The remaining Deferred Consideration is contingent upon future Nova Cell performance, pa
...